临床阶段生物制药企业MiNK治疗公司在《免疫学前沿》期刊发表经同行评审的研究报告，首次系统阐述恒定自然杀伤T细胞（iNKT）疗法在实体瘤治疗领域的重大突破。该研究揭示iNKT细胞具有独特能力，可改写肿瘤微环境并破解免疫抵抗机制，为实体瘤治疗提供了极具前景的即用型平台技术。
核心研发管线agenT-797疗法展现出突破性疗效：在不依赖淋巴清除或复杂预处理方案的情况下，该疗法对实体瘤产生持久抗肿瘤活性。最新临床报告显示，采用agenT-797联合抗PD-1疗法治疗的转移性睾丸癌患者实现完全缓解。同步推进的MiNK-215疗法采用IL-15装甲化设计，通过靶向成纤维细胞活化蛋白（FAP）的CAR-iNKT技术，直击耐药肿瘤的基质屏障难题。
临床前数据证实，MiNK-215在纤维化肿瘤模型中展现出双重机制：强效耗竭基质屏障的同时显著提升免疫细胞浸润度，为攻克耐药性实体瘤开辟全新路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.